Astrocytoma

The findings of this study suggest that PDD may be less effective in the surgery of astrocytic tumors of the spinal cord compared with those of the brain. Verifying the molecular differences of astrocytic tumors between the spinal cord and brain in a large number of cases will be necessary in future studies.

P1/2, N=58, Active, not recruiting, Queensland Institute of Medical Research | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Oct 2025

We report 10-years old child with recurrent PA harboring concurrent BRAFV600E and TP53 mutations, emphasizing the potential biological significance of this dual-mutant genotype. This case supports the growing recognition that specific molecular variants may identify children at increased risk of early tumor regrowth despite initial gross total resection.

P2, N=120, Active, not recruiting, NRG Oncology | Trial completion date: Jun 2027 --> Jul 2026

P1/2, N=33, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

Both LAK and CIK therapies could be beneficial for glioma patients, with CIK being safer and associated with higher efficacy. Although larger clinical trials are needed to consolidate observed outcomes.

Correlation with lipogenic activation of sterol response element (SRE) in hepatocarcinoma cells, was more complex. CRT response was diverse revealing ligands with theoretical full agonist, partial agonist, antagonist, inverse agonist, and other signatures within the same chemical series, suggesting the scope for precision CRT to guide nonlipogenic LXR agonist design.

Most patients with PXA-associated tumor-related epilepsy achieved seizure freedom after initial resection. Seizure recurrence was strongly associated with tumor recurrence at long-term follow up. ATRX loss was associated with seizure freedom at the most recent follow up, suggesting that tumor molecular features may help prognosticate epilepsy outcomes. Nearly one-third of patients had previously unrecognized focal seizures highlighting the importance of a detailed, anatomically guided seizure history.

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is an important biomarker because it is associated with reduced DNA repair capacity and increased sensitivity to alkylating agents, particularly temozolomide (TMZ)...Because MGMT methylation is biologically continuous, this review further argues that borderline results should be reported as gray-zone or intermediate categories when validated, and that quantitative methylation values should be integrated into subtype-aware multivariable models rather than being reduced exclusively to binary calls. This review summarizes the biological and clinical relevance of MGMT promoter methylation across glioma subtypes and proposes a subtype-aware, treatment-conditional, and assay-aware framework for interpreting its predictive and survival-related significance.

However, elevated expression of poliovirus receptor (PVR) and the immune checkpoint T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) on tumor-infiltrating leukocytes suggests a potential resistance mechanism to virotherapy. Combining rQNestin34.5 v.2 with TIGIT blockade enhances therapeutic efficacy compared to monotherapy, identifying IDH1-R132H as a potential predictive biomarker for oncolytic virotherapy response.

P3, N=408, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jul 2026